MedTrace Logo

Treatment of Upper Extremity Deep-Vein Thrombosis

NCT00245856 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2013-02-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to document the long-term outcome or prognosis of patients diagnosed with upper extremity deep-vein thrombosis who are treated with Fragmin (dalteparin sodium injection) for three months.

Conditions

  • Deep-Vein Thrombosis

Interventions

DRUG

Dalteparin sodium injection

200units/kg subcutaneous daily for one month, followed by 150units/kg subcutaneous daily for two additional months or 200 units/kg subcutaneously daily for 5 days followed by warfarin.

DRUG

Warfarin

Titrated to INR 2-3 through study month 3

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Suman W. Rathbun, M.D. · University of Oklahoma Health Science Center, Dept of Medicine/CardioVascular section

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Primary Completion
2009-03-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00245856 on ClinicalTrials.gov